NUWE vs. NRXS, XAIR, NXL, LFWD, ICU, BTCY, CODX, PAVM, PSTV, and ALUR
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include NeurAxis (NRXS), Beyond Air (XAIR), Nexalin Technology (NXL), ReWalk Robotics (LFWD), SeaStar Medical (ICU), Biotricity (BTCY), Co-Diagnostics (CODX), PAVmed (PAVM), Plus Therapeutics (PSTV), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry.
Nuwellis vs.
Nuwellis (NASDAQ:NUWE) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
Nuwellis has a net margin of -169.54% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Nuwellis' return on equity.
Nuwellis received 22 more outperform votes than NeurAxis when rated by MarketBeat users. However, 100.00% of users gave NeurAxis an outperform vote while only 54.76% of users gave Nuwellis an outperform vote.
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 26.4% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NeurAxis has lower revenue, but higher earnings than Nuwellis. NeurAxis is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeurAxis had 4 more articles in the media than Nuwellis. MarketBeat recorded 10 mentions for NeurAxis and 6 mentions for Nuwellis. NeurAxis' average media sentiment score of 0.37 beat Nuwellis' score of -0.41 indicating that NeurAxis is being referred to more favorably in the news media.
Nuwellis currently has a consensus target price of $17.00, indicating a potential upside of 1,768.13%. Given Nuwellis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuwellis is more favorable than NeurAxis.
Nuwellis has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500.
Summary
NeurAxis beats Nuwellis on 10 of the 18 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:NUWE) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy NUWE Stock Free NUWE Stock Alerts